Dengue hemorrhagic fever with special emphasis on immunopathogenesis

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 30, Issue 5-6, 2007, Pages 329-340

  Kurane, Ichiro ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Dengue fever; Dengue hemorrhagic fever; Dengue virus; Immunopathogenesis

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CYTOKINE; DENGUE VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; NONNEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; YELLOW FEVER VACCINE;

ARTICLE; BLEEDING TENDENCY; CLINICAL FEATURE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CROSS REACTION; CYTOKINE RELEASE; DENGUE; DENGUE VIRUS; DISEASE CLASSIFICATION; DISEASE MODEL; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INSECT BITE; MEDIATOR RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; SEROTYPE; SHOCK; THROMBOCYTOPENIA; VACCINE PRODUCTION; VIRUS VIRULENCE;

COMPLEMENT ACTIVATION; CYTOKINES; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; HUMANS;

DENGUE VIRUS;

EID: 34548827693     PISSN: 01479571     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cimid.2007.05.010     Document Type: Article

References (39)

1. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11 (1998) 480-496
2. Burke D.S., and Monath T.P. Flaviviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields virology (2001), Lippincott Williams & Wilkins, Philadelphia, USA 1043-1125
3. Lindenbach B.D., and Rice C.M. Flaviviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields virology (2001), Lippincott Williams & Wilkins, Philadelphia, USA 991-1041
4. Monath T.P., and Tsai T.F. Flaviviruses. In: Richman D.D., Whitley R.J., and Hayden F.G. (Eds). Clinical virology (2002), ASM Press, Washington, DC 1097-1151
5. World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment and control (1997), World Health Organization, Geneva p. 12-23
6. Nimmannitya S. Dengue hemorrhagic fever: diagnosis and management. In: Gubler D.J., and Kuno G. (Eds). Dengue and dengue hemorrhagic fever (1997), CBA International, Oxon, UK 133-145
7. Halstead S.B. Immunopathological parameters of togavirus disease syndromes. In: Schlesinger W. (Ed). The togaviruses (1980), Academic Press, New York 107-173
8. Kurane I., and Ennis F.A. Immunopathogenesis of dengue virus infections. In: Gubler D.J., and Kuno G. (Eds). Dengue and dengue hemorrhagic fever (1997), CBA International, Oxon, UK 273-290
9. Guzman M.G., Kouri G.P., Bravo J., Soler M., Vazquez S., and Morier L. Dengue hemorrhagic fever in Cuba. Am J Trop Med Hyg 42 (1990) 179-184
10. Kurane I., Mady B.J., and Ennis F.A. Antibody-dependent enhancement of dengue virus infection. Rev Med Virol 1 (1991) 211-221
11. Kliks S.C., Nisalak A., Brandt E.E., Wahl L., and Burke D.S. Antibody-dependent enhancement of dengue virus grouth in human monocytes as a factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40 (1989) 444-451
12. Kliks S.C., Nimmanitya S., Nisalak A., and Burke D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38 (1988) 411-419
13. Rico-Hesse R., Harrison L.M., Salas R.A., Tovar D., Nisalak A., Ramos C., et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 230 (1997) 244-251
14. Rico-Hesse R., Harrison L.M., Nisalak A., Vaughn D.W., Kalayanarooj S., Green S., et al. Molecular evolution of dengue type 2 virus in Thailand. Am J Trop Med Hyg 58 (1998) 96-101
15. Watts D.M., Porter K.R., Putvatana P., Vasquez B., Calampa C., Hayes C.G., et al. Failure of secondary infection with American genotype dengue 2 to cause dengue hemorrhagic fever. Lancet 354 (1999) 1431-1434
16. Leitmeyer K.C., Vaughn D.W., Watts D.M., Salas R., Villalobos I., de Chacon, et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 73 (1999) 4738-4747
17. Pandey B.D., and Igarashi A. Severity-related molecular differences among nineteen strains of dengue type 2 viruses. Microbiol Immunol 44 (2000) 179-188
18. Pandey B.D., Morita K., Hasebe F., Parquet M.C., and Igarashi A. Molecular evolution, distribution and genetic relationship among the dengue 2 viruses isolated from different clinical severity. Southeast Asian J Trop Med Public Health 31 (2000) 266-272
19. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181 (2000) 2-9
20. Rothman A.L., and Ennis F.A. Immunopathogenesis of dengue hemorrhagic fever. Virology 257 (1999) 1-6
21. Green S., and Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 19 (2006) 429-436
22. Kurane I., and Ennis F.E. Immunity and immunopathology in dengue virus infections. Semin Immunol 4 (1992) 121-127
23. Avirutnan P., Malasit P., Seliger B., Bhakdi S., and Husmann M. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol 161 (1998) 6338-6346
24. Anderson R., Wang S., Osiowy C., and Issekutz A.C. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virol 71 (1997) 4226-4232
25. King C.A., Marshall J.S., Alshurafa H., and Anderson R. Release of vasoactive cytokines by antibody-enhanced dengue virus infection of a human mast cell/basophil line. J Virol 74 (2000) 7146-7150
26. Gagnon S.J., Ennis F.A., and Rothman A.L. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4+ cytotoxic T-lymphocyte clones. J Virol 73 (1999) 3623-3629
27. Malasit P. Complement and dengue hemorrhagic fever/dengue shock syndrome. Southeast Asian J Trop Med Publ Health 18 (1987) 316-320
28. Aviruthan P., Punyadee N., Noisakran S., Komoltri C., Thiemmeca S., auethavornanan K., et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 193 (2006) 1078-1088
29. Shresta S., Sharer K.L., Prigozhin D.M., Beatty P.R., and Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80 (2006) 10208-10217
30. Bhamarapravati N., Tuchinda P., and Boonpucucknavig V. Pathology of Thailand hemorrhagic fever: a study on 100 autopsy case. Ann Trop Med Parasitol 61 (1967) 500-510
31. Yoksan S, Bhamarapravati N. Localization of dengue antigen in tissue from fatal cases of DHF. In: Proceedings of the international conference on dengue haemorrhagic fever 1982. Malaysia: University of Malaya; 1983. p. 406-10.
32. Wu S.J., Grouard-Vogel G., Sun W., Mascola J.R., Brachtel E., Putvatana R., et al. Human skin langerhans cells are targets of dengue virus infection. Nat Med 6 (2000) 816-820
33. Huerre M.R., Lan N.T., Marianneau P., Hue N.B., Khun H., Hung N.T., et al. Liver histopathology and biological correlates in five cases of fatal dengue fever in Vietnamese children. Virchows Arch 438 (2001) 107-115
34. Jessie K., Fong M.Y., Devi S., Lam S.K., and Wong K.T. Localization of dengue virus in naturally infected human tissues by immunnohistochemistry and in situ hybridization. J Infect Dis 189 (2004) 1411-1418
35. King A.D., Nisalak A., Kalayanrooj S., Myint K.S.A., Pattanapanyasat K., Nimmannitya S., et al. B cells are the principal circulating mononuclear cells infected by dengue virus. Southeast Asian J Trop Med Publ Health 30 (1999) 718-728
36. Lin Y.L., Liu C.C., Lei H.Y., Yeh T.M., Lin Y.S., Chen R.M., et al. Infection of five human liver cell lines by dengue-2 virus. J Med Virol 60 (2000) 425-431
37. Kurane I., Janus J., and Ennis F.A. Dengue virus infection of human skin fibroblasts in vitro: production of IFN-γ, IL-6 and GM-CSF. Arch Virol 124 (1992) 21-30
38. Pugachev K.V., Guirakhoo F., and Monath T.P. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 18 (2005) 384-394
39. Simasathien S., and Watanaveeradej V. Dengue vaccine. J Med Assoc Thai 88 (2005) 363-377